Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 151 to 160 of 545 total matches.
Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
Lett Drugs Ther 2019;
61:99), Table 1 should have included single-ingredient oral
formulations ...
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva, but they cost less and...
Expanded Table: Drugs for Malaria Prophylaxis (online only)
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
Pediatric
1 adult tab (250/100 mg)
once/day
5-8 kg: ½ ped tab/day (1 ped
tab is 62.5/25 mg)
9-10 kg ...
View the Expanded Table: Drugs for Prophylaxis of Malaria
Tofersen (Qalsody) for ALS
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
(ALS) in adults who
have a mutation in the superoxide dismutase 1
(SOD1) gene. About 2% of patients ...
Tofersen (Qalsody – Biogen), an intrathecally
administered antisense oligonucleotide, has received
accelerated approval from the FDA for treatment of
amyotrophic lateral sclerosis (ALS) in adults who
have a mutation in the superoxide dismutase 1
(SOD1) gene. About 2% of patients with ALS have
mutations in the SOD1 gene. Tofersen is the first drug
to be approved in the US that targets a genetic cause
of ALS. Accelerated approval of the drug was based
on the surrogate endpoint of a reduction in plasma
neurofilament light chain, which is considered likely
to predict clinical...
Med Lett Drugs Ther. 2023 Jul 24;65(1681):113-4 doi:10.58347/tml.2023.1681a | Show Introduction Hide Introduction
Omalizumab (Xolair) for Food Allergy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
, and chronic urticaria,1,2 has now
also been approved for use in conjunction with food
allergen avoidance ...
Omalizumab (Xolair – Genentech), a recombinant
anti-IgE monoclonal antibody FDA-approved for
treatment of allergic asthma, chronic rhinosinusitis
with nasal polyps, and chronic urticaria, has now
also been approved for use in conjunction with food
allergen avoidance to reduce IgE-mediated food
allergic reactions caused by accidental exposure in
patients ≥1 year old. Omalizumab is the first drug to
be approved in the US to reduce allergic reactions to
more than one food. Palforzia, an oral peanut allergen
powder, was approved in 2020 to mitigate allergic
reactions caused by...
Med Lett Drugs Ther. 2024 Apr 1;66(1699):54-6 doi:10.58347/tml.2024.1699b | Show Introduction Hide Introduction
Comparison Table: Some Nonopioid Analgesics for Pain (online only)
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
in children
$1.704
1.504
14.80
189.505,6
Salicylates
Aspirin – generic
Bayer (Bayer)
325 mg tabs; 500 ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
In Brief: Tafasitamab (Monjuvi) for Diffuse Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
on days 1 to 21 of each 28-day cycle) for up to
12 cycles, followed by tafasitamab alone until
disease ...
Tafasitamab-cxix (Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated
approval from the FDA for use in combination with
lenalidomide (Revlimid) for treatment of relapsed or
refractory diffuse large B-cell lymphoma (DLBCL),
not otherwise specified, including DLBCL arising from
low grade lymphoma, in adults who are not eligible
for autologous stem cell transplant. Accelerated
approval was based on overall response rates.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e133 doi:10.58347/tml.2023.1682d | Show Introduction Hide Introduction
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
Table 1. Pharmacology
Class ...
The FDA has approved the oral Janus kinase (JAK)
inhibitor upadacitinib (Rinvoq – Abbvie) for treatment
of moderately to severely active ulcerative colitis in
adults who have had an inadequate response to or
cannot tolerate one or more tumor necrosis factor
(TNF) inhibitors. Upadacitinib is the second JAK
inhibitor to be approved for this indication; tofacitinib
(Xeljanz) was the first. Upadacitinib is also approved
for treatment of rheumatoid arthritis, psoriatic
arthritis, atopic dermatitis, and ankylosing spondylitis.
Two New Oral Testosterone Products for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
, another
oral testosterone undecanoate formulation, was
approved for the same indication in 2019.1 ...
The FDA has approved two new oral formulations
of testosterone undecanoate — Kyzatrex (Marius)
and Tlando (Antares) — for treatment of males
with a deficiency of endogenous testosterone
due to conditions such as Klinefelter syndrome,
orchiectomy, toxic damage from chemotherapy or
alcohol, or pituitary-hypothalamic injury caused
by tumors, trauma, or radiation. Jatenzo, another
oral testosterone undecanoate formulation, was
approved for the same indication in 2019. No
testosterone products are approved for treatment of
low testosterone levels due solely to...
Dextromethorphan/Bupropion (Auvelity) for Depression
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
of pseudobulbar affect.1
Bupropion (Wellbutrin SR, Zyban, and others) is FDA-approved
in higher doses ...
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
In Brief: Hydrochlorothiazide and Skin Cancer
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
carcinoma [SCC]) to the labels of products containing
the diuretic hydrochlorothiazide.1
The labeling ...
The FDA has required the addition of information about
an increased risk of nonmelanoma skin cancer (basal
cell carcinoma [BCC] and squamous cell carcinoma
[SCC]) to the labels of products containing the diuretic
hydrochlorothiazide.